Financial and operational update about the diabetes vaccine Diamyd[®]
Diamyd Medical’s current cash position of approximately SEK 180 million supports all ongoing operational activities for the financial year as well as start-up activities for a confirmatory phase III trial with the diabetes vaccine Diamyd[® ]in both the United States and Europe that is currently being planned. The Company is also pursuing potential partnerships for future commercialization alongside discussions with potential investors, with the aim of fully financing the execution of the phase III program, the manufacturing program, and market launch as well as to facilitate pivotal